Prokop Vodicka

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.

Journal: Blood advances

Published: February 04, 2026

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Journal: Blood

Published: January 29, 2026

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Journal: Blood

Published: January 29, 2026

Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.

Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.

Journal: British journal of haematology

Published: December 10, 2025

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.

Journal: Hematological oncology

Published: July 08, 2025

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

Journal: British journal of haematology

Published: May 29, 2025

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

Journal: Leukemia & lymphoma

Published: March 31, 2025

Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?

Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?

Journal: HemaSphere

Published: March 21, 2025

Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients.

Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients.

Journal: World journal of radiology

Published: July 16, 2024

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).

Journal: British journal of haematology

Published: December 29, 2022

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.

Journal: OncoTargets and therapy

Published: August 30, 2022

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.

Journal: European journal of haematology

Published: January 02, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026